BRAF and metastatic neoplasm: The relationship between elevated baseline CEA and impaired prognosis is in line with previous studies on patients with metastatic disease.13,29,30 The present results indicate that CEA is an independent prognostic biomarker in mCRC in adjusted models including RAS/BRAF mutation status.